<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856556</url>
  </required_header>
  <id_info>
    <org_study_id>NRX1074-C-101</org_study_id>
    <nct_id>NCT01856556</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Single Intravenous and Oral Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naurex, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Naurex, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of a single
      intravenous (IV) and oral (PO) ascending dose of NRX-1074 as evidenced by the incidence and
      severity of adverse events (AEs), changes in serum chemistry, hematology, and urinalysis,
      changes in physical examination findings and subject-reported symptoms.

      The secondary objectives of this study are to assess the plasma and cerebrospinal fluid (CSF)
      pharmacokinetics (PK), the oral bioavailability of experimental formulations and the renal
      elimination through urine concentration of NRX-1074 through 24 hours following dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled, single ascending dose level study. On Day 1,
      eligibility of each subject will be confirmed, physical examination will be performed, and
      blood and urine for laboratories will be obtained. Each subject will be randomized, then will
      receive either a single IV, SC or IN dose of GLYX-13 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed and laboratory-confirmed safety</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of parent drug will be assessed over time to estimate duration of pharmacodynamics in future efficacy trials. Plasma concentration and pharmacokinetics will be related in time to observed side effects.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NRX-1074, 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRX-1074, 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRX-1074, 10 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRX-1074, 50 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRX-1074, 25 mg PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRX-1074, 125 mg PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRX-1074</intervention_name>
    <description>Single IV or PO administration</description>
    <arm_group_label>NRX-1074, 1 mg</arm_group_label>
    <arm_group_label>NRX-1074, 5 mg</arm_group_label>
    <arm_group_label>NRX-1074, 10 mg IV</arm_group_label>
    <arm_group_label>NRX-1074, 50 mg IV</arm_group_label>
    <arm_group_label>NRX-1074, 25 mg PO</arm_group_label>
    <arm_group_label>NRX-1074, 125 mg PO</arm_group_label>
    <other_name>NMDA receptor functional glycine-site partial agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single IV or PO placebo administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects

          2. Aged 18 to 55 years

          3. For female subjects, surgically sterile or at least 2 years menopausal, or using an
             acceptable method of birth control from date of screening to at least 30 days after
             the last dose of study drugIf of childbearing potential, have a documented negative
             blood or urine pregnancy test within 24 hours prior to dosing.

          4. Clinical laboratory values less than or equal to 2 times the upper limit of normal
             (ULN) or deemed not clinically significant by the Investigator.

          5. Ability to understand the requirements of the study, provide written informed consent,
             abide by the study restrictions, and agree to return for the required assessments.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace Ting, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotus Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

